Transgene Biotek - 2026 Company Profile, Team

About Transgene Biotek

Transgene Biotek is a publicly listed company based in Mardi (India) founded in 1990. Immunotherapies and drug delivery solutions for cancer are developed. Its Indian entity Transgene Biotek Limited. reported revenue of ₹36 Lakh. Transgene Biotek offers products and services including Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.

Company details

Founded in 1990 and based in Mardi, India, focus is placed on biotechnology within the oncology sector. RNAi and siRNA technologies, along with humanized monoclonal antibodies, are advanced for cancer treatments. An HIV vaccine and a multiple sclerosis drug are being developed using B-cell targeting methods. Oral formulations of insulin, monoclonal antibodies, and HIV therapies are created through the TRABI platform.

Headquarters Mardi, India
Stage Public
Sectors
Healthcare
Email
••••••••
Phone
•••• ••••
Website transgenebiotek.com
Social LinkedIn
Legal Name Transgene Biotek Limited.

Operational Areas

Healthcare → Genomics & Gene Therapy Platforms

Healthcare → Immunology & Cancer Therapeutics

Healthcare → Oncology

Key Metrics

Market Cap
₹17.65 Cr
TRABI · BSE
Share Price
₹2.57
+10.30% today
Revenue
₹0.21 Cr
FY 2025-26 · -19.2% YoY
EBITDA
−₹0.54 Cr
Margin -257.1%
Net Profit
−₹1.65 Cr
FY 2025-26 · -142.7% YoY

Associated legal entities of Transgene Biotek

Transgene Biotek is associated with 3 registered companies on The Company Check; the primary company is Transgene Biotek Limited., a listed company. Each company page carries the filings, financials, charges and directors of that entity.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Directors	Company page
Transgene Biotek Limited. Listed CIN L85195TG1990PLC011065	Active	01 Mar 1990	Ida Bollaram, Telangana	₹0.4 Cr	6	View details
Neodel Pharma Private Limited CIN U24299TG2021PTC149719	Active	17 Mar 2021	Hyderabad, Telangana		2	View details
Peroral Bio Private Limited CIN U24230TG2020PTC147169	Strike Off	23 Dec 2020	Sangareddy, Telangana		2	View details

Products & Services of Transgene Biotek

Transgene Biotek offers a comprehensive portfolio of products and services, including Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems.

Oncology Therapies

Therapeutics

Develops treatments for cancer through research platforms

Auto-Immunity Solutions

Therapeutics

Creates therapies for immune disorders via biogenerics

Biogenerics Portfolio

Biotechnology

Provides generic biologics for various medical applications

Drug Delivery Systems

Delivery Platforms

Innovates methods for effective drug administration

Board of directors of Transgene Biotek Limited. (Transgene Biotek)

Transgene Biotek Limited. is the primary company behind Transgene Biotek. The boards of the 3 registered companies of Transgene Biotek currently have 5 directors; the longest-serving is Sujana Kadiam, appointed in 2015. 8 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Sujana Kadiam DIN 07167872	Director	17 Apr 2015	11 yrs 6 mo	Transgene Biotek Limited., Peroral Bio Private Limited
Santhosh Kumar DIN 08658555	Director	12 Nov 2019	6 yrs 11 mo	Transgene Biotek Limited.
Kollipara Koteswara Rao DIN 02287235	Managing Director	04 Mar 2020	6 yrs 7 mo	Transgene Biotek Limited., Peroral Bio Private Limited, Neodel Pharma Private Limited
Swetha Marri DIN 08754103	Director	03 Jun 2020	6 yrs 5 mo	Transgene Biotek Limited.
Viswanath Toshniwal DIN 06862637	Director	17 Mar 2021	5 yrs 7 mo	Neodel Pharma Private Limited

IPO & Listings of Transgene Biotek

Transgene Biotek is a publicly listed company on the BSE with ticker symbol TRABI in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date17 Dec 1993
Listed onBSE: 526139
Listed entityTransgene Biotek Limited.
Exchange sectorHealth technology
ISININE773D01018
Share price₹2.68 (+1.13% on the day) · 2026-10-14
Market capitalisation₹17.4 Cr
EPS (diluted, trailing year)₹-0.21
Volume (last session)3,202

Financials of Transgene Biotek

Exchange-reported figures of Transgene Biotek Limited., the listed company behind Transgene Biotek (BSE: TRABI).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹0.21 Cr

-19.2% YoY

EBITDA

−₹0.54 Cr

+52.2% YoY

Profit After Tax

−₹1.65 Cr

-142.6% YoY

Net Worth

-

Total Assets

-

Total Debt

-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	0.21	0.26	0.23	0.06	0.09	0.17	0.00
Revenue growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
EBITDA	(0.54)	(1.13)	(0.60)	(0.60)	(0.45)	(0.52)	(0.86)
EBITDA margin	-257.1%	-434.6%	-260.9%	-1000.0%	-500.0%	-305.9%	-
Profit before tax	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)
Balance sheet
Total assets	-	140	140	140	145	149	159
Net worth	-	10.03	10.71	11.37	17.38	22.24	32.67
Total debt	-	14.52	14.00	13.11	12.01	11.33	10.33
Cash & bank	-	0.28	0.01	0.00	0.02	0.02	0.04
Net working capital	-	(3.06)	(1.11)	(1.26)	(1.26)	(6.74)	(6.96)
Cash flow
Cash from operations	-	1.20	0.00	0.00	0.10	0.01	0.14
Cash from investing	-	(1.70)	0.00	(0.01)	(0.10)	(0.03)	0.00
Cash from financing	-	0.78	0.00	0.00	0.00	0.00	(0.20)

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.06	0.05	0.05	0.05	0.05	0.08	0.08	0.06
Revenue growth (YoY)	+20.0%	-37.5%	-37.5%	-16.7%	0.0%	-	-	-
Other income	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04
EBITDA	(0.06)	(0.28)	(0.06)	(0.08)	(0.14)	(0.54)	(0.09)	(0.08)
EBITDA margin	-100.0%	-560.0%	-120.0%	-160.0%	-280.0%	-675.0%	-112.5%	-133.3%
Depreciation	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02
Interest	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02
Profit before tax	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
EPS (₹)	(0.05)	(0.06)	(0.05)	(0.05)	(0.06)	(0.09)	(0.01)	(0.01)

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	0.21	0.26	0.23	0.06	0.09	0.17	0.00
Revenue growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
EBITDA	(0.54)	(1.13)	(0.60)	(0.60)	(0.45)	(0.52)	(0.86)
EBITDA margin	-257.1%	-434.6%	-260.9%	-1000.0%	-500.0%	-305.9%	-
Profit before tax	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)
Balance sheet
Total assets	-	29.99	30.33	30.29	35.37	39.72	49.32
Net worth	-	(7.55)	(6.87)	(6.21)	(0.20)	4.66	15.10
Total debt	-	14.52	14.00	13.12	12.02	11.33	10.33
Cash & bank	-	0.28	0.01	0.00	0.02	0.01	0.04
Net working capital	-	(2.96)	(1.02)	(1.16)	(1.16)	(6.64)	(6.86)
Cash flow
Cash from operations	-	1.20	0.00	0.00	0.10	0.01	0.14
Cash from investing	-	(1.70)	0.00	(0.01)	(0.10)	(0.04)	0.00
Cash from financing	-	0.78	0.00	0.00	0.00	0.00	(0.20)

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.06	0.05	0.05	0.05	0.05	0.08	0.08	0.06
Revenue growth (YoY)	+20.0%	-37.5%	-37.5%	-16.7%	0.0%	-	-	-
Other income	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04
Total expenses	0.12	0.33	0.11	0.13	0.19	0.62	0.17	0.14
EBITDA	(0.06)	(0.28)	(0.06)	(0.08)	(0.14)	(0.54)	(0.09)	(0.08)
EBITDA margin	-100.0%	-560.0%	-120.0%	-160.0%	-280.0%	-675.0%	-112.5%	-133.3%
Depreciation	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02
Interest	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02
Profit before tax	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.06	0.05	0.05	0.05	0.05	0.08	0.08	0.06
Revenue growth (YoY)	+20.0%	-37.5%	-37.5%	-16.7%	0.0%	-	-	-
Other income	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04
EBITDA	(0.06)	(0.28)	(0.06)	(0.08)	(0.14)	(0.54)	(0.09)	(0.08)
EBITDA margin	-100.0%	-560.0%	-120.0%	-160.0%	-280.0%	-675.0%	-112.5%	-133.3%
Depreciation	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02
Interest	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02
Profit before tax	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
EPS (₹)	(0.05)	(0.06)	(0.05)	(0.05)	(0.06)	(0.09)	(0.01)	(0.01)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	0.21	0.26	0.23	0.06	0.09	0.17	0.00
Revenue growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
Other income	0.15	0.78	0.18	0.18	0.21	0.27	0.18
Total expenses	0.75	1.39	0.83	0.66	0.54	0.69	0.86
Employee cost	0.00	0.31	0.31	0.30	0.29	0.25	0.29
EBITDA	(0.54)	(1.13)	(0.60)	(0.60)	(0.45)	(0.52)	(0.86)
EBITDA margin	-257.1%	-434.6%	-260.9%	-1000.0%	-500.0%	-305.9%	-
Depreciation	0.20	0.09	0.09	4.95	9.92	9.91	9.90
Interest	1.06	0.24	0.14	0.62	0.23	0.27	0.38
Profit before tax	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	-	75.77	75.77	75.77	75.77	75.77	75.77
Reserves & surplus	-	(65.74)	(65.06)	(64.40)	(58.39)	(53.53)	(43.10)
Shareholders' funds (net worth)	-	10.03	10.71	11.37	17.38	22.24	32.67
Minority interest	-	0.00	0.00	0.00	0.00	0.00	0.00
Secured loans	-	6.10	4.93	4.80	4.62	4.39	4.13
Unsecured loans	-	8.42	9.07	8.31	7.39	6.94	6.20
Total debt	-	14.52	14.00	13.11	12.01	11.33	10.33
Total liabilities	-	140	140	140	145	149	159
Assets
Gross block	-	109	108	108	108	108	108
Net block	-	7.97	6.36	6.45	11.40	21.33	31.20
Capital work in progress	-	1.87	1.87	1.87	1.87	1.87	1.87
Investments	-	0.10	0.10	0.10	0.10	0.00	0.00
Inventories	-	0.03	0.03	0.03	0.09	0.02	0.04
Sundry debtors	-	0.01	0.01	0.01	0.01	0.01	0.01
Cash & bank balances	-	0.28	0.01	0.00	0.02	0.02	0.04
Loans & advances	-	0.94	1.06	1.00	0.58	0.60	0.60
Total current assets	-	1.26	1.11	1.04	0.70	0.65	0.69
Total current liabilities	-	4.32	2.22	2.30	1.96	7.39	7.65
Net working capital	-	(3.06)	(1.11)	(1.26)	(1.26)	(6.74)	(6.96)
Total assets	-	140	140	140	145	149	159

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	-	0.01	0.00	0.02	0.01	0.04	0.10
Net cash from operating activities	-	1.20	0.00	0.00	0.10	0.01	0.14
Net cash from investing activities	-	(1.70)	0.00	(0.01)	(0.10)	(0.03)	0.00
Net cash from financing activities	-	0.78	0.00	0.00	0.00	0.00	(0.20)
Net change in cash	-	0.28	0.00	(0.01)	0.00	(0.01)	(0.06)
Closing cash	-	0.28	0.01	0.00	0.02	0.02	0.04

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
EBITDA growth	+52.2%	-88.3%	0.0%	-33.3%	+13.5%	+39.5%	-
PBT growth	-142.7%	-4.6%	+89.2%	+42.4%	+0.4%	+4.8%	-24.7%
Net income growth	-142.7%	-4.6%	+89.2%	+42.4%	+0.4%	+4.8%	-
Revenue CAGR (3Y)	+51.8%	+42.4%	+10.6%	-	+8.7%	+12.3%	-100.0%
EBITDA CAGR (3Y)	-3.5%	+35.9%	+4.9%	-11.3%	-12.9%	-37.2%	-30.5%
Profitability & leverage
Net income margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
Return on capital employed	-	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Return on net worth	-	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Debt / equity	-	1.38	1.23	0.87	0.59	0.39	0.26
Long-term debt / equity	-	0.54	0.45	0.34	0.24	0.16	0.11
Interest cover	-143.24	-19.67	-20.29	-11.17	-2.22	-2.59	-3.53
Efficiency & per share
Fixed asset turnover	-	0.00	0.00	0.00	0.00	0.00	0.00
Inventory turnover	-	8.67	7.67	1.00	1.64	5.67	0.00
Debtors turnover	-	26.00	23.00	6.00	9.00	17.00	0.00
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	0.00	1.32	1.41	1.50	2.29	2.94	4.31

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.06	0.05	0.05	0.05	0.05	0.08	0.08	0.06
Revenue growth (YoY)	+20.0%	-37.5%	-37.5%	-16.7%	0.0%	-	-	-
Other income	0.00	0.15	0.00	0.00	0.00	0.04	0.04	0.04
Total expenses	0.12	0.33	0.11	0.13	0.19	0.62	0.17	0.14
EBITDA	(0.06)	(0.28)	(0.06)	(0.08)	(0.14)	(0.54)	(0.09)	(0.08)
EBITDA margin	-100.0%	-560.0%	-120.0%	-160.0%	-280.0%	-675.0%	-112.5%	-133.3%
Depreciation	0.04	0.05	0.05	0.05	0.05	0.02	0.02	0.02
Interest	0.29	0.28	0.27	0.26	0.25	0.19	0.02	0.02
Profit before tax	(0.39)	(0.46)	(0.38)	(0.39)	(0.44)	(0.71)	(0.09)	(0.08)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	0.21	0.26	0.23	0.06	0.09	0.17	0.00
Revenue growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
Other income	0.15	0.78	0.18	0.18	0.21	0.27	0.18
Total expenses	0.75	1.39	0.83	0.66	0.54	0.69	0.86
Employee cost	0.00	0.31	0.31	0.30	0.29	0.25	0.29
EBITDA	(0.54)	(1.13)	(0.60)	(0.60)	(0.45)	(0.52)	(0.86)
EBITDA margin	-257.1%	-434.6%	-260.9%	-1000.0%	-500.0%	-305.9%	-
Depreciation	0.20	0.09	0.09	4.95	9.92	9.91	9.90
Interest	1.06	0.24	0.14	0.62	0.23	0.27	0.38
Profit before tax	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net profit	(1.65)	(0.68)	(0.65)	(5.99)	(10.39)	(10.43)	(10.96)
Net profit margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	-	75.77	75.77	75.77	75.77	75.77	75.77
Reserves & surplus	-	(83.32)	(82.64)	(81.98)	(75.97)	(71.11)	(60.67)
Shareholders' funds (net worth)	-	(7.55)	(6.87)	(6.21)	(0.20)	4.66	15.10
Secured loans	-	6.10	4.93	4.80	4.62	4.39	4.13
Unsecured loans	-	8.42	9.07	8.32	7.40	6.94	6.20
Total debt	-	14.52	14.00	13.12	12.02	11.33	10.33
Total liabilities	-	29.99	30.33	30.29	35.37	39.72	49.32
Assets
Gross block	-	109	108	108	108	108	108
Net block	-	7.96	6.36	6.45	11.40	21.33	31.20
Capital work in progress	-	1.87	1.87	1.87	1.87	1.87	1.87
Investments	-	0.10	0.10	0.11	0.11	0.01	0.00
Inventories	-	0.03	0.03	0.03	0.09	0.02	0.04
Sundry debtors	-	0.00	0.00	0.00	0.00	0.00	0.00
Cash & bank balances	-	0.28	0.01	0.00	0.02	0.01	0.04
Loans & advances	-	0.94	1.06	1.00	0.58	0.60	0.60
Total current assets	-	1.25	1.10	1.03	0.69	0.63	0.68
Total current liabilities	-	4.21	2.12	2.19	1.85	7.27	7.54
Net working capital	-	(2.96)	(1.02)	(1.16)	(1.16)	(6.64)	(6.86)
Total assets	-	29.99	30.33	30.29	35.37	39.72	49.32

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	-	0.01	0.00	0.02	0.01	0.04	0.10
Net cash from operating activities	-	1.20	0.00	0.00	0.10	0.01	0.14
Net cash from investing activities	-	(1.70)	0.00	(0.01)	(0.10)	(0.04)	0.00
Net cash from financing activities	-	0.78	0.00	0.00	0.00	0.00	(0.20)
Net change in cash	-	0.28	0.00	(0.01)	0.00	(0.02)	(0.06)
Closing cash	-	0.28	0.01	0.00	0.02	0.01	0.04

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	-19.2%	+13.0%	+283.3%	-33.3%	-47.1%	-	-
EBITDA growth	+52.2%	-88.3%	0.0%	-33.3%	+13.5%	+39.5%	-
PBT growth	-142.7%	-4.6%	+89.2%	+42.4%	+0.4%	+4.8%	-24.7%
Net income growth	-142.7%	-4.6%	+89.2%	+42.4%	+0.4%	+4.8%	-
Revenue CAGR (3Y)	+51.8%	+42.4%	+10.6%	-	+8.7%	+12.3%	-100.0%
EBITDA CAGR (3Y)	-3.5%	+35.9%	+4.9%	-11.3%	-12.9%	-37.2%	-30.5%
Profitability & leverage
Net income margin	-785.7%	-261.5%	-282.6%	-9983.3%	-	-6135.3%	-
Return on capital employed	-	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Return on net worth	-	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Debt / equity	-	0.00	0.00	0.00	5.23	1.10	0.47
Long-term debt / equity	-	0.00	0.00	0.00	2.09	0.45	0.20
Interest cover	-143.24	-19.67	-20.29	-11.17	-2.22	-2.59	-3.53
Efficiency & per share
Fixed asset turnover	-	0.00	0.00	0.00	0.00	0.00	0.00
Inventory turnover	-	8.67	7.67	1.00	1.64	5.67	0.00
Debtors turnover	-	0.00	0.00	0.00	0.00	0.00	0.00
EPS (₹)	(0.22)	(0.09)	(0.09)	(0.79)	(1.37)	(1.38)	(1.45)
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	0.00	(1.00)	(0.91)	(0.82)	(0.03)	0.62	1.99

Web traffic of Transgene Biotek

The website of Transgene Biotek (transgenebiotek.com) receives about 1.4K visits a month.

Monthly visits
1.4K
▲ 63.4% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Transgene Biotek

Transgene Biotek Gets SEBI Order Freezing Co's Assets And Bank Accounts

Reuters • 9 months ago

Transgene Biotek reports consolidated net loss of Rs 0.43 crore in the June 2025 quarter | Capital Market News - Business Standard

Business Standard • 1 year ago

Transgene Biotek announces board meeting date

India Infoline • 1 year ago

Transgene Biote Consolidated September 2024 Net Sales at Rs 0.06 crore, up 30% Y-o-Y

Moneycontrol • 1 year ago

Transgene Biote Standalone June 2024 Net Sales at Rs 0.05 crore, down 50.75% Y-o-Y

Moneycontrol • 2 years ago

Transgene To Start Large-scale Trials Of New Aids Drug

Domain-B • 2 years ago

MSD to support Transgene and BioInvent led oncolytic virus clinical trial

Biopharma-Reporter • 4 years ago

Transgene Biotek To Raise $40m Via GDR Issue

Moneycontrol • 5 years ago

Transgene Biotek Inks Deal With Neodel Pharma on Oral, Nasal Formulations For COVID-19 Vaccine Under Development

Reuters • 5 years ago

Transgene, NEC, BostonGene collaborate for ovarian and head & neck cancers trials

Biospectrumasia • 6 years ago

Premium access

Complete news archive for Transgene Biotek

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Transgene Biotek

When was Transgene Biotek founded?

Transgene Biotek was founded in 1990.

Where is Transgene Biotek located?

Transgene Biotek is headquartered in Mardi, India. It is registered at Mardi, Himachal Pradesh, India.

What is the annual revenue of Transgene Biotek?

The primary company behind Transgene Biotek, Transgene Biotek Limited., reported revenue of ₹36 Lakh for FY 2026, down 19% year on year.

What does Transgene Biotek do?

Founded in 1990 and based in Mardi, India, focus is placed on biotechnology within the oncology sector. RNAi and siRNA technologies, along with humanized monoclonal antibodies, are advanced for cancer treatments. An HIV vaccine and a multiple sclerosis drug are being developed using B-cell targeting methods. Oral formulations of insulin, monoclonal antibodies, and HIV therapies are created through the TRABI platform.

What products or services does Transgene Biotek offer?

Transgene Biotek offers Oncology Therapies, Auto-Immunity Solutions, Biogenerics Portfolio, and Drug Delivery Systems.

Is Transgene Biotek publicly traded?

Yes, Transgene Biotek is publicly traded on BSE under the ticker symbol TRABI.

Which legal entities are associated with Transgene Biotek?

Transgene Biotek is associated with 3 legal entities: Transgene Biotek Limited., Peroral Bio Private Limited, Neodel Pharma Private Limited.

Who are the directors of Transgene Biotek?

The legal entities of Transgene Biotek currently have 7 directors, including Kollipara Koteswara Rao, Ankita Jain, Sujana Kadiam and others.